Edesa Biotech prices $25 million public offering of shares and warrants
The company priced 3,870,500 common shares with warrants at $5.50 combined, expecting net proceeds of about $23.1 million.
SEC filing (3)
Latest
2 stories
Thursday, August 20
Thursday, August 13
Edesa reports fiscal Q3 2026 results, readies EB06 vitiligo trial and ARDS data
Company says site activation for its Phase 2 EB06 vitiligo study is underway with enrollment expected in coming weeks, while new ARDS/AKI analyses show mortality benefit for paridiprubart.
SEC filing